Add like
Add dislike
Add to saved papers

Neutrophil-to-lymphocyte ratio is a negative prognostic biomarker for luminal A breast cancer.

Gland Surgery 2023 March 32
BACKGROUND: Inflammation plays an important role in the occurrence, development, and metastasis of tumors. However, the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in patients with luminal A breast cancer has rarely been reported in the literature. The purpose of this study was to investigate the relationship between preoperative peripheral blood NLR and the survival rate of patients with luminal A breast cancer.

METHODS: Data from 226 eligible patients with luminal A breast cancer at the Chongqing University Cancer Hospital between 2011 and 2016 were obtained. The cut-off value for NLR for predicting overall survival (OS) rate was obtained from the receiver operating characteristic (ROC) curve. The baseline characteristics of 2 groups were compared using the Chi-square test or Fisher's exact test, and OS was estimated using the Kaplan-Meier method. Cox analysis was performed to determine the correlation between clinicopathological parameters and prognosis.

RESULTS: ROC curve analysis showed that the cutoff value for NLR to predict OS was 2.0. Kaplan-Meier analysis revealed that the OS of patients with a NLR <2.0 was significantly longer than that of patients with a higher NLR >2 (P<0.0001). The area under the curve (AUC) for NLR to predict OS was 0.781 [95% confidence interval (CI): 0.712-0.851], sensitivity was 54.17%, and specificity was 97.06%. In univariate Cox regression analysis, NLR, tumor (T) stage (T3-T4 vs . T1-T2), and histological grade (II-III vs . I) were all significantly associated with OS. In multivariate Cox regression analysis, NLR and histology grade (II-III vs . I) were independent prognostic factors for OS.

CONCLUSIONS: The results suggested that higher preoperative NLR was associated with worse prognosis in luminal A breast cancer.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app